☆ 4.4 Letter

Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities

JOURNAL OF CLINICAL LIPIDOLOGY (2016)

Journal

JOURNAL OF CLINICAL LIPIDOLOGY

Volume 10, Issue 5, Pages 1278-1279

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jacl.2016.07.003

Keywords

-

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia

Takahito Doi, Mika Hori, Mariko Harada-Shiba, Yu Kataoka, Daisuke Onozuka, Kunihiro Nishimura, Ryo Nishikawa, Kosuke Tsuda, Masatsune Ogura, Cheol Son, Yoshihiro Miyamoto, Teruo Noguchi, Hiroaki Shimokawa, Satoshi Yasuda

Summary: Patients with both LDLR and PCSK9 gene variants have higher levels of LDL cholesterol and increased risk of cardiovascular events, particularly nonfatal myocardial infarction. These patients require more intensive antiatherosclerotic management.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Review Medicine, General & Internal

Genetic and molecular architecture of familial hypercholesterolemia

Marianne Abifadel, Catherine Boileau

Summary: Atherosclerotic cardiovascular disease is a major cause of death worldwide, and familial hypercholesterolemia (FH) is a commonly inherited disease with significant risks. Advances in genetic research have greatly improved the diagnosis and treatment of FH, providing more therapeutic options.

JOURNAL OF INTERNAL MEDICINE (2023)

Add to Collection

Article Hematology

Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?

J. P. P. . Silvino, M. G. Carvalho, E. A. Reis, A. P. L. Mota, K. B. Gomes, R. C. F. Duarte, M. C. J. Guimaraes, M. C. R. Sousa, P. S. Azevedo, I. F. O. Silva

Summary: This study found that FH patients treated with combination therapy (statin + ezetimibe) showed significant improvements in total cholesterol, LDL cholesterol, and thrombin generation potential. Additionally, PCSK9 levels were correlated with lipid profile and thrombin generation, and were influenced by age.

THROMBOSIS RESEARCH (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia

Hayato Tada, Kan Yamagami, Nobuko Kojima, Junichi Shibayama, Tetsuo Nishikawa, Hirofumi Okada, Akihiro Nomura, Soichiro Usui, Kenji Sakata, Masayuki Takamura, Masa-aki Kawashiri

Summary: The study revealed that the prevalence of APOE7 mutant among patients clinically diagnosed with FH was higher than expected, especially among those without other causative mutations. This suggests that APOE7 mutant may be one of the causes of FH, particularly in individuals without FH mutations.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Arianna Toscano, Maria Cinquegrani, Michele Scuruchi, Antonino Di Pino, Salvatore Piro, Viviana Ferrara, Carmela Morace, Alberto Lo Gullo, Egidio Imbalzano, Francesco Purrello, Giovanni Squadrito, Roberto Scicali, Giuseppe Mandraffino

Summary: This study evaluated the impact of PCSK9 plasma levels on pulse wave velocity (PWV) and the effect of PCSK9 inhibitors (PCSK9-i) on circulating PCSK9 and PWV in HeFH subjects. The results showed that PCSK9 levels were associated with baseline PWV values in HeFH subjects, and the variations in PCSK9 levels seemed to be correlated with PWV changes on LLT.

BIOMOLECULES (2022)

Add to Collection

Review Engineering, Chemical

Proprotein Convertase Subtilisin/Kexin Type 9 Gene Variants in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

Nang Hoang Pham, Phuong Kim Truong, Thuan Duc Lao, Thuy Ai Huyen Le

Summary: PCSK9 gene mutations are associated with lipid metabolism and atherosclerotic cardiovascular disease. GOF and LOF mutations have a higher proportion in Asia and Africa, with the first and second exons being identified as hot spots for mutation in PCSK9.

PROCESSES (2021)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

Rodrigo Alonso, Ovidio Muniz-Grijalvo, Jose Luis Diaz-Diaz, Daniel Zambon, Raimundo de Andres, Raquel Arroyo-Olivares, Francisco Fuentes-Jimenez, Juan Sanchez Munoz-Torrero, Jose Cepeda, Rocio Aguado, Pilar Alvarez-Banos, Marta Casanas, Marta Dieguez, Maria Dolores Manas, Patricia Rubio, Rosa Argueso, Francisco Arrieta, Pablo Gonzalez-Bustos, Leopoldo Perez-Isla, Pedro Mata

Summary: The study shows that PCSK9 inhibitors can significantly reduce LDL-C levels in patients with familial hypercholesterolemia in clinical practice and improve the achievement of LDL-C targets.

JOURNAL OF CLINICAL LIPIDOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Meng Chai, Yongming He, Wang Zhao, Xuebin Han, Guoyan Zhao, Xueping Ma, Ping Qiao, Dongmei Shi, Yuyang Liu, Wei Han, Pei An, Haoyu Li, Shuling Yan, Qingyang Ma, Huan Deng, Lei Qian, Yujie Zhou

Summary: This study is the first randomized placebo-controlled clinical trial conducted in China to assess the efficacy and safety of tafolecimab in patients with HeFH. It was found that treatment with tafolecimab significantly reduced LDL-C levels and had a favorable safety profile in Chinese patients with HeFH.

BMC MEDICINE (2023)

Add to Collection

Review Chemistry, Medicinal

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside

Anandita Agarwala, Renato Quispe, Anne C. Goldberg, Erin D. Michos

Summary: Bempedoic acid is a first-in-class oral inhibitor of cholesterol biosynthesis approved for use in patients with ASCVD and HeFH, with promising results in lowering LDL-C levels. The ongoing CLEAR Outcomes trial will provide further insights into its placement among non-statin lipid-lowering therapy options.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection

Review Peripheral Vascular Disease

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

Archna Bajaj, Marina Cuchel

Summary: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extreme elevations of low-density lipoprotein cholesterol (LDL-C), requiring aggressive treatment to prevent premature atherosclerotic cardiovascular disease (ASCVD). The treatment landscape for HoFH has rapidly progressed over the last decade, with the addition of several new therapy options such as PCSK9 inhibitors, lomitapide, and ANGPTL3 inhibitors. Lipoprotein apheresis and gene therapy may also be necessary for some patients.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia

Julia Brandts, Kanika Dharmayat, Antonio J. Vallejo-Vaz, Mansour Taghavi Azar Sharabiani, Rebecca Jones, John J. P. Kastelein, Frederick J. Raal, Kausik K. Ray

Summary: The study revealed that among patients diagnosed clinically as HeFH, the LDL-C reduction effect of PCSK9-targeting medications remains consistent regardless of different drug classes and genetic variants.

ATHEROSCLEROSIS (2021)

Add to Collection

Article Pediatrics

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians

Ljiljana Bjelakovic, Lazar Stosic, Aleksandra Klisic, Marko Jovic, Sanja Stankovic, Aleksandra Stankovic, Sasa Pantelic, Danijela Zivkovic, Vladimir Vukovic, Bojko Bjelakovic

Summary: This study investigated the awareness and knowledge of familial hypercholesterolemia (FH) among pediatricians in Serbia. The results showed that although most pediatricians had knowledge about the genetic inheritance and long-term health risks of FH, there was a substantial lack of practical clinical knowledge, and a low awareness of international guidelines for FH drug treatment.

FRONTIERS IN PEDIATRICS (2023)

Add to Collection

Article Medicine, General & Internal

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia

Amy L. Peterson, Matthew Bang, Robert C. Block, Nathan D. Wong, Dean G. Karalis

Summary: Many physicians do not conduct cascade screening and are less likely to screen individuals with family history of known HeFH, compared to those with high cholesterol or premature ASCVD family history. Most physicians are willing to screen pediatric patients but only a few are willing to start treatment at recommended ages. Further education is needed to improve the diagnosis and treatment of HeFH.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

Patrice Marques, Elena Domingo, Arantxa Rubio, Sergio Martinez-Hervas, Juan F. Ascaso, Laura Piqueras, Jose T. Real, Maria-Jesus Sanz

Summary: Inhibiting PCSK9 function can impact systemic inflammation and endothelial dysfunction by constraining leukocyte-endothelium interactions, enhancing T-regulatory cell activation, and reducing inflammatory response.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events

Hayato Tada, Hirofumi Okada, Akihiro Nomura, Atsushi Nohara, Masakazu Yamagishi, Masayuki Takamura, Masa-aki Kawashiri

Summary: This study aimed to evaluate the prognostic impact of cascade screening for patients with familial hypercholesterolemia (FH). The results showed that patients identified through cascade screening were on average younger and had a lower risk for major adverse cardiac events (MACE) under milder lipid-lowering therapies compared to the probands.

JOURNAL OF CLINICAL LIPIDOLOGY (2021)

Add to Collection

Review Pathology

Improving the detection of familial hypercholesterolaemia

Nick S. R. Lan, Andrew C. Martin, Tom Brett, Gerald F. Watts, Damon A. Bell

PATHOLOGY (2019)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

PCSK9 in HIV infection: New opportunity or red herring?

Massimiliano Ruscica, Gerald F. Watts, Cesare R. Sirtori

ATHEROSCLEROSIS (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia

Alpo Vuorio, Gerald F. Watts, Petri T. Kovanen

ATHEROSCLEROSIS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Interactions between cadherin-11 and platelet-derived growth factor receptor-alpha signaling link cell adhesion and proliferation

Bhanupriya Madarampalli, Gerald F. M. Watts, Paul M. Panipinto, Hung N. Nguygen, Michael B. Brenner, Erika H. Noss

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)

Add to Collection

Article Endocrinology & Metabolism

Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it

Nick S. R. Lan, P. Gerry Fegan, Bu B. Yeap, James M. Rankin, Gerald F. Watts

DIABETES OBESITY & METABOLISM (2019)

Add to Collection

Article Pharmacology & Pharmacy

Comparative aspects of the care of familial hypercholesterolemia in the Ten Countries Study

Jing Pang, Dick C. Chan, Miao Hu, Lauretta A. Muir, See Kwok, Min-Ji Charng, Christopher M. Florkowski, Peter M. George, Jie Lin, Do Doan Loi, A. David Marais, Hapizah M. Nawawi, Lourdes E. Gonzalez-Santos, Ta-Chen Su, Thanh Huong Truong, Raul D. Santos, Handrean Soran, Brian Tomlinson, Shizuya Yamashita, Zanfina Ademi, Gerald F. Watts

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

Add to Collection

Article Nutrition & Dietetics

The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients

Kenneth Yong, Trevor Mori, Gerard Chew, Lawrence J. Beilin, Ian Puddey, Gerald F. Watts, Ashley Irish, Gursharan Dogra, Neil Boudville, Wai Lim

JOURNAL OF RENAL NUTRITION (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia

Katrina L. Ellis, Leopoldo Perez de Isla, Rodrigo Alonso, Francisco Fuentes, Gerald F. Watts, Pedro Mata

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Status of PCSK9 Monoclonal Antibodies in Australia

Daniel J. Scherer, Adam J. Nelson, Richard O'Brien, Karam M. Kostner, David L. Hare, David M. Colquhoun, Philip J. Barter, Philip Aylward, Stephen J. Nicholls, Gerald F. Watts

HEART LUNG AND CIRCULATION (2019)

Add to Collection

Article Pharmacology & Pharmacy

Impact of PCSK9 inhibitors on plasma lipoprotein (a) concentrations with or without a background of niacin therapy

Bruce A. Warden, Jessica Minnier, Gerald F. Watts, Sergio Fazio, Michael D. Shapiro

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study

Claudia Stefanutti, Jing Pang, Serafina Di Giacomo, Xue Wu, Xumin Wang, Claudia Morozzi, Gerald F. Watts, Jie Lin

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

Add to Collection

Article Immunology

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry

Fan Zhang, Kevin Wei, Kamil Slowikowski, Chamith Y. Fonseka, Deepak A. Rao, Stephen Kelly, Susan M. Goodman, Darren Tabechian, Laura B. Hughes, Karen Salomon-Escoto, Gerald F. M. Watts, A. Helena Jonsson, Javier Rangel-Moreno, Nida Meednu, Cristina Rozo, William Apruzzese, Thomas M. Eisenhaure, David J. Lieb, David L. Boyle, Arthur M. Mandelin, Brendan F. Boyce, Edward DiCarlo, Ellen M. Gravallese, Peter K. Gregersen, Larry Moreland, Gary S. Firestein, Nir Hacohen, Chad Nusbaum, James A. Lederer, Harris Perlman, Costantino Pitzalis, Andrew Filer, V. Michael Holers, Vivian P. Bykerk, Laura T. Donlin, Jennifer H. Anolik, Michael B. Brenner, Soumya Raychaudhuri, Jennifer Albrecht, S. Louis Bridges, Christopher D. Buckley, Jane H. Buckner, James Dolan, Joel M. Guthridge, Maria Gutierrez-Arcelus, Lionel B. Ivashkiv, Eddie A. James, Judith A. James, Josh Keegan, Yvonne C. Lee, Mandy J. McGeachy, Michael A. McNamara, Joseph R. Mears, Fumitaka Mizoguchi, Jennifer P. Nguyen, Akiko Noma, Dana E. Orange, Mina Rohani-Pichavant, Christopher Ritchlin, William H. Robinson, Anupamaa Seshadri, Danielle Sutherby, Jennifer Seifert, Jason D. Turner, Paul J. Utz

NATURE IMMUNOLOGY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials

Federica Fogacci, Maciej Banach, Dimitri P. Mikhailidis, Eric Bruckert, Peter P. Toth, Gerald F. Watts, Zeljko Reiner, John Mancini, Manfredi Rizzo, Olena Mitchenko, Daniel Pella, Zlatko Fras, Amirhossein Sahebkar, Michal Vrablik, Arrigo F. G. Cicero

PHARMACOLOGICAL RESEARCH (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Recent advances in synthetic pharmacotherapies for dyslipidaemias

Cesare R. Sirtori, Shizuya Yamashita, Maria Francesca Greco, Alberto Corsini, Gerald F. Watts, Massimiliano Ruscica

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)

Add to Collection

Review Pharmacology & Pharmacy

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Nasim Kiaie, Armita Mahdavi Gorabi, Peter E. Penson, Gerald Watts, Thomas P. Johnston, Maciej Banach, Amirhossein Sahebkar

DRUG DISCOVERY TODAY (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.